Results 11 to 20 of about 4,832 (178)

Benralizumab monotherapy was insufficient to induce remission in patients with active eosinophilic granulomatosis with polyangiitis

Respiratory Medicine Case Reports, 2022
Eosinophils play an important pathogenetic role in the development of eosinophilic granulomatosis with polyangiitis (EGPA). EGPA has long been treated with systemic corticosteroids and immunosuppressive agents.
Osamu Matsuno, Seijiro Minamoto
doaj   +2 more sources

Population Pharmacokinetics and Pharmacodynamics of Benralizumab in Healthy Volunteers and Patients With Asthma

CPT: Pharmacometrics & Systems Pharmacology, 2017
Benralizumab is a humanized, afucosylated, anti‐interleukin‐5 receptor α, immunoglobulin G (IgG) 1 κ monoclonal antibody. We developed a population pharmacokinetic (PK)/pharmacodynamic (PD) model for benralizumab by analyzing PK and blood eosinophil ...
B Wang, L Yan, Z Yao, LK Roskos
doaj   +2 more sources

Efficacy and safety of benralizumab in elderly patients with severe eosinophilic asthma

European Clinical Respiratory Journal
Background Biologics are the important drugs for severe asthma, but clinical trials included few elderly patients. Data on the safety and efficacy of benralizumab in elderly asthma patients are limited.Methods This clinical study was a multicentre ...
Kohei Somekawa, Keisuke Watanabe, Kenichi Seki, Suguru Muraoka, Ami Izawa, Ayami Kaneko, Yukiko Otsu, Momo Hirata, Sousuke Kubo, Katsushi Tanaka, Ryo Nagasawa, Hiromi Matsumoto, Kota Murohashi, Hiroaki Fuji, Ayako Aoki, Nobuyuki Horita, Yu Hara, Nobuaki Kobayashi, Makoto Kudo, Takeshi Kaneko   +19 more
doaj   +2 more sources

Benralizumab, an add-on treatment for severe eosinophilic asthma: evaluation of exacerbations, emergency department visits, lung function, and oral corticosteroid use

Therapeutics and Clinical Risk Management, 2018
Diego Jose Maselli,1 Linda Rogers,2 Jay I Peters1 1Division of Pulmonary Diseases and Critical Care, University of Texas Health, San Antonio, TX, USA; 2Division of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine Mount Sinai &ndash ...
Maselli DJ, Rogers L, Peters JI
doaj   +1 more source

Benralizumab treatment in an elderly patient with eosinophilic esophagitis resulted in remission: a case report

BMC Geriatrics
Background Interleukin-5 (IL-5) has recently been shown to play a crucial role in eosinophil-mediated diseases, implying that an IL-5 receptor alpha chain (IL-5Rα) antibody (benralizumab) can be effective against eosinophilic esophagitis (EoE).
Azusa Ishii, Tomofumi Shibata, Yohei Tsunoda, Takafumi Kayukawa, Masahiro Kobayashi, Masami Orinaka, Shoko Miyamatsu, Yoshio Ryuge, Shuichi Asano, Ichidai Tanaka   +9 more
doaj   +2 more sources

Real-life study of the cost-effectiveness of benralizumab vs previous care in Bulgaria [PDF]

Pharmacia
The aim is to evaluate the cost-effectiveness of benralizumab therapy in real-life settings in Bulgaria in comparison with previous care. The point of view is that of the national health insurance fund, and the time horizon is for one year.
Konstantin Tachkov, Petya Milushewa, Guenka Petrova   +2 more
doaj   +4 more sources

Effect of benralizumab treatment on the airway microbiome in COPD

ERJ Open Research
Background One-third of patients with COPD have an eosinophilic inflammatory phenotype. Benralizumab is an afucosylated humanised monoclonal antibody that targets the interleukin-5 receptor α subunit, leading to rapid and near-complete eosinophil ...
Koirobi Haldar, Vijay Mistry, Mathew Richardson, Corinne Hamblet, Maria Jison, Michael R. Barer, Christopher McCrae, Christopher E. Brightling   +7 more
doaj   +2 more sources

Benralizumab Reduces Respiratory Exacerbations and Oral Glucocorticosteroid Dose in Patients with Severe Asthma and Eosinophilic Granulomatosis with Polyangiitis

Journal of Asthma and Allergy
Carlo Mümmler,1 Pontus Mertsch,1 Michaela Barnikel,1 Frank Haubner,2 Ulf Schönermarck,3 Ulrich Grabmaier,4 Hendrik Schulze-Koops,5 Jürgen Behr,1 Nikolaus Kneidinger,1,6 Katrin Milger1 1Department of Medicine V, LMU University Hospital, LMU Munich ...
Mümmler C, Mertsch P, Barnikel M, Haubner F, Schönermarck U, Grabmaier U, Schulze-Koops H, Behr J, Kneidinger N, Milger K   +9 more
doaj   +2 more sources

Real-World Experience with Benralizumab in Patients with Severe Eosinophilic Asthma: A Case Series [PDF]

Journal of Asthma and Allergy, 2021
Francesco Menzella,1 Marco Bonavia,2 Matteo Bonini,3 Maria D’Amato,4 Salvatore Lombardo,5 Nicola Murgia,6 Vincenzo Patella,7,8 Massimo Triggiani,9 Girolamo Pelaia10 1Pneumology Unit, Arcispedale Santa Maria Nuova, Azienda USL di Reggio Emilia-IRCCS,
Menzella F, Bonavia M, Bonini M, D'Amato M, Lombardo S, Murgia N, Patella V, Triggiani M, Pelaia G   +8 more
doaj   +2 more sources

Sputum Streptococcus pneumoniae is reduced in COPD following treatment with benralizumab

International Journal of COPD, 2019
Leena George,1 Adam Wright,1 Vijay Mistry,1 Amanda Sutcliffe,1 Latifa Chachi,1 Koirobi Haldar,1 Mohammadali Yavari Ramsheh,1 Matthew Richardson,1 René van der Merwe,2 Ubaldo Martin,3 Paul Newbold,3 Christopher E Brightling11Department of ...
George L, Wright A, Mistry V, Sutcliffe A, Chachi L, Haldar K, Ramsheh MY, Richardson M, van der Merwe R, Martin U, Newbold P, Brightling CE   +11 more
doaj   +2 more sources